Comparative Pharmacology
Head-to-head clinical analysis: ELAPRASE versus LUMIZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAPRASE versus LUMIZYME.
ELAPRASE vs LUMIZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
0.58 mg/kg IV once weekly administered over 1 hour
5 mg/kg administered intravenously once every 2 weeks.
None Documented
None Documented
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy